HCV Treatment
Survey Finds Most Primary Care Providers Unaware of New Hepatitis C Drugs
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 10 July 2014 00:00
- Written by Decision Resources Group
Nearly 75% of primary care physicians are unfamiliar with the most recently approved direct-acting antiviral drugs for hepatitis C, and about two-thirds are unaware of even the first-generation antivirals available since 2011, according to a recent survey by Decision Resources Group.
Studies Look at Hepatitis C Care Cascade and Healthcare Utilization
- Details
- Category: HCV Treatment
- Published on Thursday, 03 July 2014 00:00
- Written by Liz Highleyman
Half of people with hepatitis C in the U.S. are aware of their infection, but fewer than 10% have been successfully treated and achieved sustained virological response (SVR), according to a meta-analysis published July 2 in the open-access journal PLoS ONE. Despite these gaps in testing, care, and treatment, hepatitis C accounts for a substantial share of healthcare utilization, especially among baby boomers, a related study found.
European Regulators Give Positive Opinion on Daclatasvir for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 27 June 2014 00:00
- Written by Bristol-Myers Squibb
Bristol-Myers Squibb announced this week that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its hepatitis C virus (HCV) NS5A inhibitor daclatasvir, which has been given the brand name Daklinza.
Boehringer Ingelheim Discontinues Faldaprevir, Halts HCV Drug Development
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 27 June 2014 00:00
- Written by Boehringer Ingelheim
Boehringer Ingelheim has announced that it will discontinue development of its investigational hepatitis C virus (HCV) protease inhibitor faldaprevir, will withdraw pending approval requests, and will not proceed with further work in this area due to rapid changes in the hepatitis C treatment environment.
AbbVie's 3D Hepatitis C Combo Gets Priority Review in U.S. and Europe
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 19 June 2014 00:00
- Written by AbbVie
AbbVie's all-oral 3-drug combination regimen for genotype 1 chronic hepatitis C has been granted priority review status by the U.S. Food and Drug Administration (FDA), putting it on track for approval by the end of the year. In related news, the company announced last week that Marketing Authorization Applications for the 3D regimen have been validated and are under accelerated assessment by the European Medicines Agency (EMA), with a decision expected in early 2015.
Web Design and Development by